← Back to Clinical Trials
RecruitingNCT03242642

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionMitral Valve Regurgitation
SponsorMedtronic Cardiovascular
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment1,056
SexALL
Min Age18 Years
Max AgeN/A
Start Date2017-10-23
Completion2027-05-30
Interventions
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.

Eligibility Criteria

Inclusion Criteria: * Moderate to severe or severe symptomatic mitral regurgitation * Local site multidisciplinary heart team experienced in mitral valve therapies agrees that the subject is unsuitable for treatment with approved transcatheter repair or conventional mitral valve intervention Exclusion Criteria: * prior transcatheter mitral valve procedure with device currently implanted * anatomic contraindications * prohibitive mitral annular calcification * left ventricular ejection fraction \<25% * need for emergent or urgent surgery * hemodynamic instability

Related Trials